Chicago, IL 的 多發性骨髓瘤 臨床試驗
22 項針對 多發性骨髓瘤 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
招募中1 期
- University of Chicago Medical Center /ID# 278863, Chicago
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Chicago
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
招募中1/2 期
- University of Chicago Medical Center, Chicago
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Rush University System for Health, Chicago
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- University Of Illinois Medical Center, Chicago
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
招募中4 期
- Northwestern University, Chicago
- University of Chicago, Chicago
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
招募中2 期
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Cancer Treatment Centers of America-Chicago, Chicago
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
招募中2 期
- University of Illinois at Chicago, Chicago
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
招募中3 期
- Endeavor Health - Swedish Hospital, Chicago
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
招募中3 期
- Advocate Illinois Masonic Medical Center, Chicago
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Chicago
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
招募中
- Northwestern University Feinberg School of Medicine, Chicago
Personalized Autologous Transplant for Multiple Myeloma
招募中1 期
- University Illinois Chicago, Chicago
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
招募中3 期
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of Chicago, Chicago
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
招募中1 期
- University of Chicago Medical Center, Chicago
Hypofractionation (Radiation) Trial for Multiple Myeloma
招募中1 期
- The University of Chicago Comprehensive Cancer Center, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Northwestern, Chicago
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
招募中1 期
- University of Illinois Cancer Center, Chicago
其他城市的 多發性骨髓瘤 試驗
- New York City, NY60 項研究
- Boston, MA42 項研究
- Atlanta, GA41 項研究
- Houston, TX38 項研究
- Durham, NC37 項研究
- Nashville, TN32 項研究
- Denver, CO27 項研究
- Rochester, MN24 項研究
- St. Louis, MO24 項研究
- Columbus, OH24 項研究
- Baldwin Park, CA23 項研究
- Seattle, WA22 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌58 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肥胖症41 項研究
- 肺癌41 項研究
- 卵巢癌36 項研究
- 中風34 項研究
- 大腸直腸癌33 項研究
- 心臟衰竭31 項研究
- 過重28 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。